- Time of issue:2022-08-15 14:34:24
At Bivision Pharma, we strive to transform patients’ lives by developing an integrated, image-guided, next-generation approach to targeted radionuclide therapy.
While the current commercially available radiopharmaceuticals are mostly conventional therapeutics and targeted radiotracers, our focus is to bring theranostics to the market to improve treatment outcomes for cancer patients. The word “theranostics” is coined from “therapeutics” and “diagnostics”. And treatment approach with theranostics normally involves a pair of highly correlated drugs, one for diagnosis and the other for therapy. Each drug of the pair shares the same precursor but differs only in the radionuclides it chelates. This is a highly integrated approach to maximize the benefits of personalized medicine.
The progress of our pipeline is greatly enhanced by the parallel advancement of our proprietary platforms. One of the core platforms is J-Linker, which is ideally suited for holding the targeting ligand and the radionuclide together and for modulating the physiochemical properties of the molecule to improve its druggability. Currently we have four diverse programs in the pipeline and the most advanced, JH02, is expected to enter clinical development in 2023.